Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy | Health Care Economics, Insurance, Payment | JAMA | JAMA Network

https://jamanetwork.com/journals/jama/fullarticle/2847303 Enviado desde mi iPhone